Chamber and committees

The Better Together Programme, Scotland''s national patient experience programme, will be reviewing the first national datasets produced through the two national patient experience surveys undertaken in 2009-10 to establish if there are reported differences in the experiences of those people living with long term conditions including cancer. The national reports published in 2010 have highlighted differential experiences across some patient groups but not specifically those people living with cancer.

Deaths data in Scotland is sourced from General Register Office for Scotland; Data is supplied annually in September. The most recent calendar year of data currently available is 2009.

Number of deaths from prostate cancer by NHS board area of residence for calendar years 1997 to 2009.

A copy of the table has been placed in the Scottish Parliament Information Centre
(Bib. number 52499) - Table (a)

Ref: IR2011-00445.

Source: General Register Office for Scotland (GROS).

Data extracted: September 2010.

Number of deaths from prostate cancer by Scottish parliamentary constituency of residence, calendar years 1997 to 2009.

A copy of the table has been placed in the Scottish Parliament Information Centre
(Bib. number 52499) - Table (b)

Ref: IR2011-00445.

Source: General Register Office for Scotland (GROS).

Data extracted: September 2010.

More comprehensive data on prostate cancer can be found on the Information Services Division website at http://www.isdscotland.org/isd/1488.html.

In 2010 the Scottish Government circulated the prostate cancer risk management programme pack to all general practitioners across NHS Scotland. Full details of this programme can be found at:

http://www.scotland.gov.uk/Topics/Health/health/cancer/publications.

The PSA testing information leaflet, which is included in the prostate cancer risk management programme pack, is available to members of the public from their GP and can also be accessed via the Scottish Government website.

Men who are concerned about prostate cancer can ask their GP for a PSA test. If they do so, they should be provided with full information explaining the risks and benefits, allowing them to make an informed choice about proceeding with the test. The prostate cancer risk management programme pack provides all the relevant information in one concise resource.

Data on newly diagnosed cancers in Scotland are recorded on the Scottish Cancer Registry. The most recent calendar year of data currently available is 2008.

Incidence (number of registrations) and age-standardised incidence rates of prostate cancer by NHS board area of residence for calendar years 1997 to 2008.

A copy of the table has been placed in the Scottish Parliament Information Centre
(Bib. number 52498) - Table (a)

Ref: IR2011-00325.

Source: Scottish Cancer Registry, ISD.

Data extracted: February 2011.

Incidence (number of registrations) and age-standardised incidence rates of prostate cancer by Scottish parliamentary constituency of residence for calendar years 1997 to 2008.

A copy of the table has been placed in the Scottish Parliament Information Centre
(Bib. number 52498) - Table (b)

Ref: IR2011-00325.

Source: Scottish Cancer Registry, ISD.

Data extracted: February 2011.

More comprehensive data on prostate cancer can be found on the Information Services Division website at http://www.isdscotland.org/isd/1488.html.

This information is not held centrally however Table 1 shows the estimated numbers of patients attending consultations at Scottish GP practices for prostate cancer related conditions during the financial years 2003-04 to 2008-09.

Patients with prostate cancer will be diagnosed and receive treatment in healthcare settings other than GP practices, and may never consult their GP practice for prostate cancer. They may also consult their GP practice for non-prostate cancer related conditions.

These estimates are based on data from a small sample of general practices in Scotland that participate in the Practice Team Information (PTI) scheme. The patients registered to PTI practices are representative of Scotland as a whole in terms of their age, gender and deprivation profile. However, precise estimates are difficult to generate for small age groups and/or for conditions where patients consult relatively rarely. Confidence intervals are shown to indicate the degree of precision of these estimates.

Table 1

Estimated Numbers¹, with 95% Confidence Intervals², of Patients Attending Consultations with a GP or Practice-employed Nurse for Prostate Cancer, in Scotland.

Financial Year	Estimated Patients	95% Confidence Intervals	Estimated Consultations	95% Confidence Intervals
2003-04	7,471	(6,245-8,696)	27,422	(21,304-33,540)
2004-05	8,667	(7,111-10,223)	28,079	(21,556-34,602)
2005-06	7,067	(5,839-8,294)	22,188	(17,640-26,736)
2006-07	7,833	(6,184-9,482)	23,515	(17,378-29,652)
2007-08	8,146	(6,749-9,543)	22,633	(17,863-27,402)
2008-09	8,371	(7,227-9,516)	23,517	(19,667-27,368)

Notes:

1. Based on data from 59, 53, 51, 49, 48 and 58 PTI practices that submitted complete GP and practice nurse data for the years ending 31 March 2004, 2005, 2006, 2007, 2008 and 2009 respectively.

2. As the estimates are based on data from a sample of practices, 95% confidence intervals are included to indicate the relative degree of certainty of these estimates.

The following table shows the estimated level of employment in fish processing in Scotland for 2007 and for 2008, the most recent year for which data is currently available.

This includes employment in the processing of fish from Scotland''s sea fisheries and landings by vessels from other countries, processing fish from aquaculture and from imported fish. Separate figures for fish processing related specifically to sea fisheries are not available. The figures provided are headcount i.e. there is no differentiation between full and part time workers.

Year	2007	2008
Employment	7,800	7,800

 

First-sale value of landings by Scottish vessels from 2007 are as follows:

2007: £400 million

2008: £401 million

2009: £443 million

Gross value added (GVA) of the Scottish fishing industry has been estimated as follows for 2007 and for 2008:

2007: £111 million

2008: £146 million

In addition to the direct impact on Scottish GVA, sea fishing also has knock-on benefits to other parts of the economy through the associated supply chain and through induced household spending. These additional impacts are not the subject of official analysis.

All figures provided are in 2009 prices and show the most up to date data available.

The data requested is not routinely collected or held centrally.

The UK National Screening Committee (UK NSC) sets out the criteria to assess screening programmes; the introduction of proposed new population screening programmes; the modification and withdrawal of existing programmes; and the quality and management of such programmes. At present the UK NSC recommends that a national programme for prostate cancer, with the currently available testing techniques, would not be of proven benefit and could cause harm. This policy was last reviewed in December 2010 and no significant changes were made. It is due to be considered again in 2013-14 and the UK NSC will continue to actively review the research findings as they become available on screening for prostate cancer. The Chief Scientist Office (CSO) within the Scottish Government Health Directorates has responsibility for encouraging and supporting research into health and health care needs in Scotland. CSO is currently funding one research project into prostate cancer, at a cost of £364,000. This project is based at the University of Aberdeen, titled Deregulation of androgen receptor signalling in prostate cancer and will contribute to the development of UK NSC policy.

Data on the number of people who died from bowel cancer, in each year since 1999, are available for Scotland by NHS board on the Information Services Division website at:

http://www.isdscotland.org/isd/1425.html.

The most recent year for which numbers are available is 2009.